Eledon Pharmaceuticals is a clinical-stage biotechnology company focused on developing immune-modulating therapies for transplantation, autoimmune diseases, and neurodegenerative conditions. The company's lead investigational product is tegoprubart, a humanized anti-CD40L antibody that targets the CD40 ligand pathway, a well-validated biological mechanism for immune regulation. Tegoprubart is being evaluated across multiple therapeutic areas, including kidney allograft transplantation through the Phase 2 BESTOW trial, islet cell transplantation for type 1 diabetes management, and xenotransplantation procedures. The company is also exploring applications in amyotrophic lateral sclerosis treatment. Eledon's clinical development strategy encompasses Phase 2 studies demonstrating promising kidney function outcomes and favorable safety profiles compared to standard immunosuppressive regimens. The company is advancing toward Phase 3 clinical trials and regulatory discussions with the FDA. Eledon maintains active collaborations with leading transplant centers and research institutions to expand its therapeutic potential across multiple indication areas.